Skip to main content
  • En
  • Français

Top Navigation

  • Newsroom
  • Contact Us

Main navigation

  • About Us
  • Products
  • Technology
  • Clinical Studies
  • Investors
  • News
  • En
  • Français

Press Releases

Bone Therapeutics treats 12 patients without safety concerns in ALLOB® Phase IIA spinal fusion trial

  • Read more about Bone Therapeutics treats 12 patients without safety concerns in ALLOB® Phase IIA spinal fusion trial

Bone Therapeutics Provides Business Update for the Fourth Quarter of 2015

  • Read more about Bone Therapeutics Provides Business Update for the Fourth Quarter of 2015

Bone Therapeutics presents ALLOB® pre-clinical and early clinical efficacy data in spinal fusion at the Clinical Applications of Stem Cells Conference

  • Read more about Bone Therapeutics presents ALLOB® pre-clinical and early clinical efficacy data in spinal fusion at the Clinical Applications of Stem Cells Conference

Bone Therapeutics Notice of Full Year 2015 Results: Results to be announced on 29 March 2016

  • Read more about Bone Therapeutics Notice of Full Year 2015 Results: Results to be announced on 29 March 2016

Bone Therapeutics reports initial efficacy results from its PREOB® Phase IIA trial in severe osteoporosis

  • Read more about Bone Therapeutics reports initial efficacy results from its PREOB® Phase IIA trial in severe osteoporosis

Bone Therapeutics Reports Full Year 2015 Results

  • Read more about Bone Therapeutics Reports Full Year 2015 Results

Bone Therapeutics announces the publication of its Annual Report 2015

  • Read more about Bone Therapeutics announces the publication of its Annual Report 2015

The preliminary documents for the Annual General Shareholder Meeting on 26 May 2016 have been made available

  • Read more about The preliminary documents for the Annual General Shareholder Meeting on 26 May 2016 have been made available

Bone Therapeutics completes recruitment of its ALLOB®Phase IIA spinal fusion study

  • Read more about Bone Therapeutics completes recruitment of its ALLOB®Phase IIA spinal fusion study

Bone Therapeutics Provides Business Update for the First Quarter of 2016

  • Read more about Bone Therapeutics Provides Business Update for the First Quarter of 2016

Pagination

  • Previous page ‹‹
  • Next page ››
Subscribe to Press Releases
Wallonie Eu Flag

BioSenic SA
Rue Granbonpré 11 – Bâtiment H (bte 24)
1435 Mont-St-Guibert – Belgium
T.: +32 493 09 73 66
info@biosenic.com
Contact

Sign upfor our press releases

Receive information about BioSenic

Sign Up

Footer menu

  • Privacy Policy
  • Trademarks Copyrights
  • Users conditions